CoronaryAtlas logo
CoronaryAtlas
Phenylalanine
Pathway / Myocardial injury (shared endpoint)

Phenylalanine

metabolite

Branched amino acid dysregulation in acute myocardial infarction marks ischemic metabolic failure and tissue injury.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencemedium
RationaleAmino acid biomarker for AMI; elevated in acute myocardial necrosis and metabolic stress.
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresNon-Type-I-associated
R — rupture / Type-I
—
C — non-Type-I
56
A — assay feasibility
42
E — evidence strength
41
T1DI (composite)
5
Specificity differential (R−C)-40.6
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 1
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmiamag 2
2hypoxemia / respiratory failuren/a
2hypertensive emergencyn/a
2high-demand / peri-operative stressmag 1
3sudden cardiac deathmag 2
4aPCI-related periproceduralmag 2
4bstent thrombosisn/a
4cin-stent restenosismag 2
5CABG-relatedn/a
Coverage: 6/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 9 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research

Literature evidence(1)